Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Main Article Content

April W. Armstrong
Mark Lebwohl
Richard B. Warren
Howard Sofen
Shinichi Imafuku
Mamitaro Ohtsuki
Lynda Spelman
Thierry Passeron
Kim A. Papp
Renata M. Kisa
Victoria Berger
Eleni Vritzali
Kim Hoyt
Matthew J. Colombo
Subhashis Banerjee
Bruce Strober
Diamant Thaçi
Andrew Blauvelt


TYK2, deucravacitinib, plaque psoriasis, long term efficacy, long term safety


Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Deucravacitinib was superior to placebo and apremilast in the POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751) parent trials in moderate to severe plaque psoriasis. The POETYK long-term extension (LTE; NCT04036435) trial enrolled patients who completed PSO-1/PSO-2. We report safety and efficacy of deucravacitinib for up to 3 years (Week 148; through cutoff 6/15/2022).

Methods: PSO-1/PSO-2 randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily (QD), or apremilast twice daily. At Week 52, patients enrolled in the LTE received open-label deucravacitinib 6 mg QD. Safety was evaluated in patients who received ≥1 dose of deucravacitinib using exposure-adjusted incidence rate per 100 person-years (EAIR/PY). Efficacy outcomes (≥75%/≥90% reduction from baseline in Psoriasis Area and Severity Index [PASI 75/90]; static Physician Global Assessment score of 0 [clear] or 1 [almost clear] with a ≥2-point improvement from baseline [sPGA 0/1]) were analyzed using modified nonresponder imputation (mNRI) in patients who received continuous deucravacitinib treatment from Day 1 of the parent trial and were treated in the LTE.

Results: Of 1519 patients who received ≥1 dose of deucravacitinib (3294.3 PY cumulative exposure), 513 patients received continuous deucravacitinib treatment from Day 1 in PSO-1/PSO-2 and were treated in the LTE. EAIRs/100 PY were comparable, or decreased, between the 2-year and 3-year cumulative periods, respectively, for AEs (154.4, 144.8), serious AEs (6.1, 5.5), discontinuations due to AEs (2.8, 2.4), herpes zoster (0.7, 0.6), malignancies (0.9, 0.9), major adverse cardiovascular events (0.4, 0.3), venous thromboembolism (0.1, 0.1), and deaths (0.4, 0.3). Response rates were maintained at Week 148 by mNRI (PASI 75, 73.2%; PASI 90, 48.1%; sPGA 0/1, 54.1%).

Conclusion: Deucravacitinib maintained a consistent safety profile and durable efficacy for up to 3 years.


1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736.

2. Sotyktu [package insert]. Princeton, NJ: Bristol Myers Squibb; September 2022.

3. Sotyktu [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb Pharmaceutical Operations; March 2023.

4. Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K.; September 2022.

5. Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd.; December 2022.

6. Sotyktu [product monograph]. Montreal, QC, Canada: Bristol Myers Squibb Canada Co.; November 2022.

7. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995.

8. Armstrong AW, et al. J Am Acad Dermatol. 2023;88:29-39.

9. Strober B, et al. J Am Acad Dermatol. 2023;88:40-51.

10. Warren RB, et al. Presented at the 30th EADV Congress; 29 September-2 October 2021.

11. Lebwohl M, et al. Presented at the 31st EADV Congress; 7-10 September 2022; Milan, Italy.

12. Warren RB, et al. Presented at the San Diego Dermatology Symposium; March 11-13, 2022; San Diego, CA.

13. Reich K, et al. Br J Dermatol. 2021;185:1146-1159.

14. Papp K, et al. Br J Dermatol. 2021;185:1135-1145.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>